Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B

Table 1 Clinical and serological data from patients studied (mean ± SD)

Group	n	Age (yr)	HBsAg	HBeAg	Anti-HBc	HBV-DNA (IU/mL)	ALT1 (nkat/L)
Patients	25	25.7 (18-42)	+	+	+	> 2.0E + 04	2645.09 ± 1799.87
Volunteers	10	26.2 (24-32)	-	-	-	NT	311.28 ± 83.40

NT: not tested;

¹Normal range < 666.8 nkat/L.

Table 2 Expression of costimulatory molecules on DCs from different groups of patients (mean ± SD)

	n	CD1a	CD80	CD83	HLA-DR
Healthy control DC	10	39.41 ± 3.12	38.52 ± 3.18	40.76 ± 3.15	59.62 ± 4.73
CHB control DC	25	26.85 ± 2.80b	25.75 ± 2.51b	23.21 ± 3.10b	32.20 ± 3.04b
ETV-treated DC	25	29.07 ± 3.20a	28.00 ± 2.76a	25.66 ± 3.19a	41.96 ± 3.81a

^aP > 0.05 vs CHB control group;

^bP < 0.01 vs healthy control group.